Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
Status: | Enrolling by invitation |
---|---|
Conditions: | Other Indications, Other Indications, Other Indications |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | Any |
Updated: | 3/7/2019 |
Start Date: | August 31, 2018 |
End Date: | July 2024 |
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial
The overall goal of this study is to determine the clinical benefit and safety of antiviral
therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants.
We will conduct a multi-center double-blind randomized placebo-controlled trial to determine
whether hearing-impaired infants with asymptomatic cCMV have better hearing and language
outcomes if they receive valganciclovir antiviral treatment. We will also determine the
safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired
infants. This study will be unique in that the cohort enrolled will only include
hearing-impaired infants with asymptomatic cCMV.
Primary Objective: To determine if treatment of cCMV-infected hearing impaired infants with
isolated hearing loss with the antiviral drug valganciclovir reduces the maximum worsening in
left or right ear hearing 8 months after randomization compared to untreated cCMV-infected
hearing impaired infants.
Main Secondary Objectives:
1. To determine if valganciclovir treatment improves the following outcomes when compared
to the control group:
1. The risk of a clinically significant worsening of hearing defined by occurrence of
cochlear implantation due to progressive hearing loss or a ≥ 10 dB (decibel)
increase in the minimum response level (MRL) at two or more audiometric test
frequencies (from among 1 kHz, 2 kHz, and 4kHz) in either the left or right ear or
a ≥ 15 dB increase at any of these frequencies in either the left or right ear
between baseline and 8 months post-randomization.
2. The MacArthur-Bates Communicative Development Inventory (CDI) percentile score for
words produced at 22 months of age.
3. The change in the average MRL across the 2 and 4 kHz frequencies from baseline to 8
months post-randomization in the best-ear.
2. To evaluate safety measures based on all grade 3 or greater new adverse events
designated by the NIAID Division of AIDS (DAIDS) toxicity tables.
therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants.
We will conduct a multi-center double-blind randomized placebo-controlled trial to determine
whether hearing-impaired infants with asymptomatic cCMV have better hearing and language
outcomes if they receive valganciclovir antiviral treatment. We will also determine the
safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired
infants. This study will be unique in that the cohort enrolled will only include
hearing-impaired infants with asymptomatic cCMV.
Primary Objective: To determine if treatment of cCMV-infected hearing impaired infants with
isolated hearing loss with the antiviral drug valganciclovir reduces the maximum worsening in
left or right ear hearing 8 months after randomization compared to untreated cCMV-infected
hearing impaired infants.
Main Secondary Objectives:
1. To determine if valganciclovir treatment improves the following outcomes when compared
to the control group:
1. The risk of a clinically significant worsening of hearing defined by occurrence of
cochlear implantation due to progressive hearing loss or a ≥ 10 dB (decibel)
increase in the minimum response level (MRL) at two or more audiometric test
frequencies (from among 1 kHz, 2 kHz, and 4kHz) in either the left or right ear or
a ≥ 15 dB increase at any of these frequencies in either the left or right ear
between baseline and 8 months post-randomization.
2. The MacArthur-Bates Communicative Development Inventory (CDI) percentile score for
words produced at 22 months of age.
3. The change in the average MRL across the 2 and 4 kHz frequencies from baseline to 8
months post-randomization in the best-ear.
2. To evaluate safety measures based on all grade 3 or greater new adverse events
designated by the NIAID Division of AIDS (DAIDS) toxicity tables.
Cytomegalovirus (CMV) can be transmitted from the mother to the fetus and is a leading cause
of sensorineural hearing loss (SNHL), which is a condition where the inner ear is unable to
convert sound into nerve impulses to the brain. This hearing loss and its detrimental effect
on language development contribute nearly $4 billion annually to the health care costs in the
U.S. Unlike other types of SNHL, CMV induced hearing loss can be treated. Several clinical
trials have demonstrated that antiviral therapy may prevent progressive hearing loss if
administered early in life for severely affected (symptomatic CMV) infants. These promising
findings have given rise to a debate regarding the best method for identifying and treating
the more numerous asymptomatic CMV-infected infants.
One approach is to conduct universal newborn hearing screens, and then do CMV diagnostic
testing only on the infants who fail the hearing screen. This targeted approach should
identify those infants at greatest risk of developing progressive hearing loss and consequent
communicative difficulties. Utah is the first state to mandate this approach whereby infants
under three weeks of age who fail their newborn hearing screening undergo CMV testing. In
this trial, the hearing screen targeted approach will be used to identify patients eligible
for participation in a double blind placebo controlled randomized clinical trial of antiviral
valganciclovir therapy. The results of this trial will inform public policy, potentially
shift our current clinical practice regarding pediatric hearing loss evaluation, and
potentially offer a therapeutic option to asymptomatic CMV-infected infants with SNHL.
of sensorineural hearing loss (SNHL), which is a condition where the inner ear is unable to
convert sound into nerve impulses to the brain. This hearing loss and its detrimental effect
on language development contribute nearly $4 billion annually to the health care costs in the
U.S. Unlike other types of SNHL, CMV induced hearing loss can be treated. Several clinical
trials have demonstrated that antiviral therapy may prevent progressive hearing loss if
administered early in life for severely affected (symptomatic CMV) infants. These promising
findings have given rise to a debate regarding the best method for identifying and treating
the more numerous asymptomatic CMV-infected infants.
One approach is to conduct universal newborn hearing screens, and then do CMV diagnostic
testing only on the infants who fail the hearing screen. This targeted approach should
identify those infants at greatest risk of developing progressive hearing loss and consequent
communicative difficulties. Utah is the first state to mandate this approach whereby infants
under three weeks of age who fail their newborn hearing screening undergo CMV testing. In
this trial, the hearing screen targeted approach will be used to identify patients eligible
for participation in a double blind placebo controlled randomized clinical trial of antiviral
valganciclovir therapy. The results of this trial will inform public policy, potentially
shift our current clinical practice regarding pediatric hearing loss evaluation, and
potentially offer a therapeutic option to asymptomatic CMV-infected infants with SNHL.
Inclusion Criteria:
- Age greater than or equal to 1 month and less than or equal to 6 months at the time of
randomization; AND
- Greater than or equal to 37 weeks gestational age at birth; AND
- Positive congenital CMV by urine culture or polymerase chain reaction test(PCR), OR
saliva culture or PCR followed by confirmatory urine PCR by 21 days of age, OR urine
culture or PCR after 21 days of age followed by newborn dry blood spot PCR; AND
- Confirmed sensorineural hearing loss (SNHL) by auditory brainstem response (ABR)
testing. For ABR assessments, hearing loss is defined as levels greater than 25 dB
normal hearing levels (NHL) at 1, 2, or 4 kHz in one or both ears.
Exclusion Criteria:
- Imminent demise; OR
- Known hypersensitivity reaction to valganciclovir, ganciclovir, or any components of
the investigational product formulation; OR
- ALT (Alanine Aminotransferase) five times baseline U/L, hepatomegaly, or significant
gastrointestinal disorders (e.g., eosinophilic esophagitis, ulcerative colitis); OR
- Absolute neutrophil count (ANC) less than 500 cells/mm^3, Hemoglobin less than 8 g/dL,
or platelets less than 50,000/mm^3, splenomegaly, or significant hematologic disorders
(e.g., hemophilia, leukemia, sickle cell anemia); OR
- Creatinine clearance less than 60 mL/min/1.73m^2 or significant renal disorders (e.g.,
nephrotic syndrome); OR
- Potassium greater than 5.5 mEq/L; OR
- Receiving other antiviral medications or immune globulin therapy; OR
- Receiving other investigational drugs; OR
- Breast feeding from a mother receiving antiviral or immunosuppressive medication; OR
- Known HIV positive mother (risk of immunosuppression); OR
- Subject is currently using list of prohibited medication specified by the package
insert; OR
- Other known cause contributing to SNHL (e.g., meningitis, aminoglycoside ototoxicity);
OR
- Bilateral profound SNHL or auditory neuropathy spectrum disorder; OR
- Existing conductive hearing loss or mixed permanent hearing loss is present; OR
- Evidence of intracranial calcification; OR
- Evidence of hydrocephalus; OR
- Microcephaly; OR
- Presence of petechiae; OR
- Intrauterine growth retardation; OR
- Chorioretinitis, optic atrophy or pale optic nerves; OR
- Parent or guardian unable to speak English or Spanish; OR
- Subject exposed to a language other than English or Spanish a majority of the time; OR
- Subject unable to complete hearing assessments or parent/guardian unable to complete
communication questionnaires.
We found this trial at
30
sites
Click here to add this to my saved trials
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
Click here to add this to my saved trials
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
Click here to add this to my saved trials
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
Norfolk, Virginia 23507
(757) 668-7000
Children's Hospital of The King's Daughters Children
Click here to add this to my saved trials
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Rady Children's Hospital - San Diego Rady Children's Hospital-San Diego is the region’s pediatric medical...
Click here to add this to my saved trials
University of New Mexico Founded in 1889 as New Mexico’s flagship institution, the University of...
Click here to add this to my saved trials
Children's Healthcare of Atlanta Whether treating a toddler in an emergency or supporting a teen...
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
340 W 10th St #6200
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(317) 274-3772
Indiana University School of Medicine With more than 2,000 students in 2013, the Indiana University...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
Click here to add this to my saved trials
2450 Riverside Avenue
Minneapolis, Minnesota 55454
Minneapolis, Minnesota 55454
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
Click here to add this to my saved trials
Click here to add this to my saved trials
Univ of Massachusetts Med School As the commonwealth's only public medical school, we take seriously...
Click here to add this to my saved trials